AvanbulinAvanbulin
MedChemExpress (MCE)
HY-106008
798577-91-0
BAL27862
99.08%
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Room temperature in continental US
may vary elsewhere.
Avanbulin (BAL27862) is a potent, Colchicine site-binding, tubulin assembly inhibitor. Avanbulin inhibits tubulin assembly at 37 °C with an IC50 of 1.4 μM. Avanbulin binds to tubulin with an apparent Kd value of 244 nM. Avanbulin can be used for the research of cancer and cell division.
Avanbulin (0-4 μM) binds to tubulin in the site as Colchicine with an apparent Kd value of 244 nM.[1]. Avanbulin (50 μM
0, 10, 20, 30, 60 min) induces the proteolysis of tubulin[1]. Avanbulin (33 nM
0, 10, 20, 30, 60 min
HeLa-tubGFP cells) collapses the mitotic spindle and forms the tiny tubulin aggregates[1]. Avanbulin does not induce the formation of tubulin oligomers[1]. Avanbulin induces growth inhibition of 23 tumor cell lines with a median relative IC50 of 13.8 nM (96 hours) [2]. Avanbulin (6 nM and 20 nM) inhibits the migration of GBM6 and GBM9 cells[3]. Avanbulin (6 nM and 20 nM
GBM6-shEB1 and GBM6-sh0 cells) triggers astrocytic differentiation of GBM6 in an EB1-dependent manner[3]. Avanbulin (12 nM
4 h) reduces kinetochore-microtubule (KT–MT) occupancy of MG132(10 μM
2h) treated hTert-RPE1 eGFP-α-tubulin cells[4]. Avanbulin (12 nM
4 h) reduces average inter-KT distances of cells, shows intact spindle morphology, and lacks obvious chromosome alignment defects[4].
| | | |
| | | | | |
[1]. Prota AE, et al. The novel microtubule-destabilizing drug avanbulin binds to the colchicine site of tubulin with distinct effects on microtubule organization. J Mol Biol. 2014 Apr 17
426(8):1848-60. [Content Brief]
[2]. Kolb EA, et al. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun
62(6):1106-9. [Content Brief]
[3]. Bergès R, et al. The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells. Mol Cancer Ther. 2016 Nov
15(11):2740-2749. [Content Brief]
[4]. Dudka D, et al. Complete microtubule-kinetochore occupancy favours the segregation of merotelic attachments. Nat Commun. 2018
9(1):2042. Published 2018 May 23. [Content Brief]